Heparin-induced thrombocytopenia (HIT), the most common complication of heparin therapy, is also the most common form of the drug-induced thrombocytopenias. HIT is classified as type I and type II, the first being benign and the latter severe. HIT type II is attributed to an immune response characterized by complexes of heparin and platelet factor (PF) 4. Enzyme-linked immunosorbent assays allow easy and simple determination of these antibody titers; however, because specificity and sensitivity is not optimal, there is concern that the clinical relevance may be low. In clinical trials many patients were shown to form HIT-IgG in response to heparin without developing manifestations of HIT type II. Therefore, routine screening of clinically asymptomatic patients for antiheparin/ PF 4 antibodies is not recommended. HIT type II is a clinicopathologic syndrome that ideally should be confirmed by laboratory testing. If any clinical suspicion arises, however, heparin and low molecular weight heparin therapy should be discontinued and an alternative anticoagulant therapy started. Alternative drugs have been evaluated in significant numbers of patients including danaparoid and thrombin inhibitors. In the case of danaparoid, it is highly recommended that an in vitro test for cross-reactivity be performed before the onset of therapy. If testing cannot be performed, immediate administration of a thrombin inhibitor is preferred.
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Heparin has been used as an anticoagulant and as an antithrombotic agent for decades. Its use has been firmly established in many types of surgical and nonsurgical medicine. During the last 10 years, however, potential adverse reactions to heparin and other glycosaminoglycans, such as thrombocytopenia, have attracted increasing interest from clinicians. Before several key publications provided some understanding of the pathophysiological mechanism of heparin-induced thrombocytopenia, the term heparin-associated thrombocytopenia was commonly used because it was believed that additional components of the heparin preparations were responsible for the fall in platelet count. It now has been shown that there is a causal relationship between the glycosaminoglycan molecules themselves and the initiation of clinical symptoms (1) (2) (3) (4) (5) (6) (7) (8) . Therefore, the terminology of heparininduced thrombocytopenia (HIT) has now been internationally accepted. The HIT syndrome is classified as type I and type II based on apparent differences in etiology, incidence, clinical features, and more importantly, prognosis for the patient.
HIT TYPE I Heparin-induced thrombocytopenia type I is attributed to the direct activation of platelets by unfractionated or standard heparin. It is characterized by a drop in platelet count early in the course of therapy and is considered benign. Usually, the platelet count remains above 100,000/jjLL. Despite its common occurrence (possiblỹ 20% of those treated with heparin), thromboembolic complications are uncommon, and this type of HIT usually resolves despite continued administration of heparin.
HIT TYPE II
Heparin-induced thrombocytopenia type II is attributed to an immune response based on platelet activation occurring via binding of heparin to platelets or by another mechanism that leads to a release of platelet factor 4 (PF 4) from the platelet alpha granules (1, 6) . The released platelet factor (PF) 4 complexes with heparin and initiates the generation of antiheparin/PF 4 antibodies, predominantly of the IgG class. Multimolecular com-plexes comprised of heparin, PF 4, and IgG are formed on the platelet surface, leading to cross-linking of the platelet Fc-receptors (Fc'yRIIa) (3). In non-HIT studies, FcyRIIa cross-linking produces a platelet activation response leading to a conformational change in the platelet fibrinogen receptor (GPIIb/IIIa) (9), platelet aggregation, the generation of platelet-derived microparticles, and further release of granule constituents such as PF 4, triggering even more IgG-mediated platelet activation (2) . Platelet-derived microparticles have been shown to promote thrombin generation in several studies ( 10, 11 ) . Furthermore, PF 4 binds to endothelial cell heparan sulfate, resulting in HIT antibody binding to endothelial heparin/ PF 4 complexes (4, 7) . This causes endothelial cell activation and expression of endothelial tissue factor and fibrinolytic inhibitors such as plasminogen activator inhibitor-1 (PAI-1) (12) , which also contribute to thrombin generation. Thrombin activates platelets and endothelium, further contributing to the thrombotic potential. Based on this reaction cascade it has been suggested that inhibition of thrombin be considered one of the key therapeutic goals in the treatment of HIT type II (13) .
HIT type II typically occurs ~5 days after the start of heparin therapy, unless the patient had previous exposure to heparin, which may cause the clinical symptoms to occur earlier. This syndrome is characterized by a rapid drop in platelet count to <100,000/~L, or a 40-50% decrease from baseline and persists if heparin is continued. It frequently is associated with severe thrombotic complications that may occur before the decrease in platelet count. Thrombotic complications may be localized in the venous or arterial vascular system and have been frequently misinterpreted as &dquo;heparin failures.&dquo;
Validity of laboratory methods
A number of assays have been used for the laboratory diagnosis of HIT type II including various types of platelet aggregation tests, the radiolabeled serotonin release test, and antiheparin/PF 4 antibody titer enzyme-linked immunosorbent assays (ELISAs) based on the ability of the HIT-IgG to recognize heparin/PF 4 complexes bound to a solid phase (14) (15) (16) (17) (18) (19) . The platelet aggregation assays, which are the more commonly used methods for clinical diagnosis, have been documented to have optimal sensitivity to HIT type II only if performed using appropriate controls and precautions (14, 19, 20) . Due to their relative technical simplicity, these tests can be used to evaluate cross-reactivity of heparin and alternative anticoagulants (6, 18, 21) . The functional assays, platelet aggregation test, and the serotonin release test use platelet-rich plasma or washed platelets prepared fresh for each test.
The sensitivity of the antiheparin/PF 4 antibody titer assays is high (i.e., antibody titers are not uncommon in heparin-treated patients with no signs or symptoms of HIT), leading to the concern that the clinical relevance may be low. Moreover, a study of two different ELISAs resulted in differing sensitivities and specificities (16) . Flow cytometry is used to measure platelet activation (22, 23) . Using whole blood allows testing in a more physiological environment as platelets can interact with leukocytes and erythrocytes. Both cell populations have been shown to modulate the degree of platelet activation (22) . Thus, flow cytometry may be a potential tool to aid in the understanding of the pathophysiological mechanism of HIT type II and to facilitate diagnosis of this severe complication of heparin therapy.
Alternative anticoagulant options
Several studies have provided evidence that HIT type II is associated with a prothrombotic state due to the heparin-induced generation of procoagulant plateletderived microparticles (19, (22) (23) (24) . Therefore, there is a need to administer an immediate-acting anticoagulant until the platelet counts indicate that the acute phase of the disease is over. At this point, an oral anticoagulant is given. This is true for patients with and without clinically manifest thromboembolic complications. Several alternative anticoagulants for use in the acute phase of HIT have been evaluated in significant numbers of patients.
Low molecular weight heparins
Before the pathophysiological mechanism of HIT type II was understood, (i.e., when HIT type I and HIT type II were believed to be of common origin), low molecular weight heparins (LMWHs) were given to patients with clinical symptoms of HIT. Despite the fact that the LMWHs have been shown to have a high in vitro crossreactivity rate (78-88% of patient sera positive with heparin were also positive with LMWH [5, 18] ), there are reports of some patients recovering from their clinical symptoms of HIT while being treated with LMWH (25) (26) (27) . However, because of the high frequency of heparin cross-reactivity and the availability of compounds exhibiting lower or no cross-reactivity, LMWHs are not considered to be the ideal substitute for heparin. If a LMWH is to be used, it is strongly recommended that crossreactivity be excluded before administration to patients with HIT.
Danaparoid
In Germany and in the United States, the factor Xa-inhibiting substance danaparoid sodium (Orgarang;
Organon International B.V., Oss, The Netherlands) is available for compassionate use in HIT type II patients. Orgarang is a heterogeneous mixture of glycosaminoglycuronans, heparan sulfate (approximately 84%), dermatan sulfate (approximately 12%), and a small amount (up to 5%) of chondroitin sulfate, isolated from animal intestinal mucosa. The final product has been shown by physicochemical analyses to be free of heparin. The heparan sulfate fraction includes a small subfraction (ap-proximately 5%) with a high affinity for antithrombin (AT) III. This subfraction is responsible for Orgaran's s antifactor Xa activity and about half of its AT activity. The dermatan sulfate fraction also mediates a portion of the AT activity via heparin cofactor II. The anti-Xa to AT IIa ratio of OrgaranO is at least 22, which clearly differentiates it from heparin and LMWHs, which have ratios of 1 to 5 (28) . The intravenous half-life of Orgarang is approximately 18 hours. Orgarang has a 12-15% cross-reactivity to heparin-induced antibodies using in vitro test systems (18) . Nevertheless, it has been used successfully in some patients with HIT (28). Argatroban Argatroban (NovastanO, Texas Biotechnology Corp., Houston, TX, U.S.A.) is a low molecular weight (532 d), synthetic drug derived from L-arginine. It directly binds to the catalytic site of thrombin and has a short elimination half-life of <1 hour. Novastang has been in clinical trials in Japan since 1980 for prophylaxis and treatment of venous and arterial thrombosis and disseminated intravascular coagulation (DIC). The structure of Novastang is completely different from heparin and has never shown cross-reactivity in any in vitro assay for HIT (18) . The argatroban (ARG) 911 clinical trial showed successful use of this drug for the treatment and prophylaxis of thrombotic events in patients with HIT (31, 32) . Additional uses of Novastan~ for cardiovascular interventional procedures, such as stent placement and angioplasty, in patients with HIT were also successful (33) .
Experimental studies and clinical experiences
Antiheparin/P F 4-induced antibodies in heparin or
LMWH-treated patients
There is limited reported evidence that LMWH causes fewer cases of HIT type II and less antibody formation than heparin. In a prospective study comparing LMWH and heparin after elective hip surgery, Warkentin and coworkers (34) studied the incidence of thrombocytopenia in 665 patients and the presence of heparindependent IgG antibodies using the 14C-serotonin release test in a subgroup of 387 patients. Therapy was continued for no more than 2 weeks (mean 10 days) at a dose of 30 mg b.i.d. subcutaneous for the LMWH enoxaparin and 7500 U b.i.d. subcutaneous for heparin. Defined as two consecutive platelet counts of less than 150,000/~.~,L occurring 5=5 days after the start of the antithrombotic therapy and a positive 14C-serotonin release test, HIT occurred in 9 of 332 patients treated with heparin. Eight of these nine patients developed a thromboembolic complication ; seven were venous including two cases of pulmonary embolism. The one arterial occlusion involved the superior mesenteric artery. None of the 333 patients who received LMWH had a platelet count <150,000/)JLL. IgG-antibodies developed in 4 (2.2%) of 182 LMWHtreated patients. This was significantly less than the 7.8% incidence of antibody formation in the 205 heparin patients evaluated.
We have performed a double-blind, multicentric, controlled trial in patients undergoing elective total hip replacement and compared the antithrombotic efficacy and safety of a single daily dose of 5000 anti-Xa U LMWH (certoparin; Novartis Pharma GmbH, Nurnberg, Germany) compared with 5000 IU heparin t.i.d. Certoparin is prepared by chemical cleavage of heparin using isoamylnitrite in acidic medium. The mean molecular weight ranges from 5000 to 7000 d (90% below 10,000 d), as determined by gel filtration chromatography. In both groups, subcutaneous prophylaxis was started in the morning of the operation day and continued for 12 to 14 days. All patients were screened by bilateral venography for deep vein thrombosis (DVT). In the presence of clinical suspicion of DVT, venography was performed earlier. Clinical symptoms of pulmonary embolism were verified by scintigraphy. In 288 patients, blood samples were drawn before the first injection of LMWH or heparin, on the first and seventh postoperative day and on the last day of prophylaxis (days [12] [13] [14] . Antiheparin/PF 4 antibodies were measured by a commercially available ELISA (Diagnostica Stago, Asnieres, France).
At the end of prophylaxis, positive antiheparin/PF 4 antibody titers were detected in 31 % of patients in the heparin group, and 16% of the patients treated with LMWH had a positive ELISA test (p < .O1) (35) . Thrombocytopenia did not occur in either group, and the positive ELISA result did not correlate with DVT, proven by venography, or pulmonary embolism (Table 1) .
Antiheparin/PF 4 antibody titers were also measured in 81 patients treated with intravenous heparin (20 U/kg/ h) or certoparin given intravenously (14 anti-Xa U/kg/h) or subcutaneously (4000 anti-Xa U b.i.d.) for 16 days ( Table 2 ). The antibody titer had a time-dependent increase in each treatment group despite an absence of TABLE 1. Heparin-induced thrombocytopenia in orthopedic patients receiving heparin or low molecular weight prophylaxis Incidence of HIT in patients randomized to receive either 5000 anti-Xa U certoparin subcutaneous daily or 5000 IU heparin subcutaneous t.i.d. as DVT prophylaxis following elective hip replacement (35) . De- spite not observing thrombocytopenia in any of the patients treated with either heparin or LMWH, 31 % of heparin-treated and 16% of LMWHtreated patients exhibited positive antiheparin/PF 4 antibody titers (HPIA) at the end of treatment (12 to 14 days). Antibody formation was significantly higher in patients treated with heparin (p < .01).
LMWH, low molecular weight heparin; HIT, heparin-induced thrombocytopenia; DVT, deep vein thrombosis. thrombocytopenia. The number of patients with a positive titer ranged from >50% in the intravenous heparin group to 25% in the subcutaneous LMWH group (29) .
The data of these several studies suggest that heparin and LMWH are capable of inducing antiheparin/PF 4 antibody formation even at low prophylactic doses, but that this antibody titer is not necessarily associated with thrombocytopenia or clinical symptoms of HIT. These data further suggest that LMWH is less likely to generate the heparin/PF 4 antibodies than heparin.
Cross-reactivity of LMWHs with antiheparin/PF 4 antibodies
We examined the cross-reactivity of three LMWHs with HIT type II positive sera using the 14C_serotonin release test (21) . Each LMWH was tested at two low ( 1 and 2.5 anti-Xa U/mL) and two high concentrations (50 and 100 anti-Xa U/mL) with 25 HIT-positive sera with heparin by platelet aggregation and by an ELISA method for antiheparin/PF 4 antibodies. In addition, purified antibodies from 5 HIT patients were studied. Heparin and the LMWHs caused the release of serotonin at low concentrations from the platelets obtained from multiple donors (Fig. 1 ). The release reaction was blocked at con- 1 . The ability of LMWHs to cross-react with HIT IgG was tested using the serotonin release test. Washed platelets from several donors were incubated with HIT-positive serum (n = 25) or purified HIT antibody (n = 5) and dilutions of either heparin or LMWH, tested at equivalent anti-Xa U levels. At low concentrations, the response measured as % serotonin release was comparable for heparin and the LMWHs. At high concentrations (>50 anti-Xa U/mL), the release induced by heparin was inhibited, but a significantly larger release was observed for all LMWHs. centrations >50 anti-Xa U/mL only for heparin. The degree of serotonin release in the presence of the low concentrations of the LMWHs was the same as that measured in the presence of heparin (eight-to tenfold higher than normal serum; p > .05). In contrast to heparin, a significant release of serotonin was observed in the presence of 50 anti-Xa U/mL of each of the LMWHs (60-80% maximum release). While the amount released was less than that observed with the lower concentrations, the degree of release (threeto fourfold by normal serum) was such that the samples would be considered positive.
Whether this differential concentration response has a clinical correlate remains to be determined. The three LMWHs did not respond differently from each other.
The cross-reactivity of LMWHs was also determined using whole blood flow cytometry where donor whole blood (multiple donors were studied) was mixed with patient serum (n = 30) and heparin, LMWH, or the AT III-binding heparin-pentasaccharide. All agents were supplemented at equal anti-Xa unit concentrations. The LMWHs (certoparin, enoxaparin, and reviparin) produced identical platelet activation responses as heparin when platelet microparticle generation or P-selectin expression was measured (Fig. 2 ). Only the pentasaccharide was observed to be devoid of interaction with the HIT serum.
FIG. 2. The ability of LMWHs to cross-react with
HIT immunoglobulins was tested using whole blood flow cytometry. Donor whole blood (multiple donors) was stirred in the presence of HIT serum (n = 20) and either heparin, LMWH or the heparinpentasaccharide. Platelet activation was assessed by measuring the formation of platelet microparticles. The level of microparticles formed (and P-selectin expression, not shown here) in the presence of the LMWHs was comparable to that formed with heparin. Only pentasaccharide failed to induce microparticle formation (and P-selectin expression) induced by HIT serum.
The data of these studies correlates well with our previous data (18) using the platelet aggregation test for HIT, in that all tested LMWHs showed a positive response for platelet activation/aggregation in systems positive for heparin.
Comparative studies of 14C-serotonin release . and immunoassays Serum samples from patients with suspected HIT type II (n = 105) were evaluated by the 14C-serotonin release test and two antiheparin/PF 4 antibody ELISAs. Samples were obtained from two patient groups: certoparintreated patients, not exhibiting a decrease in platelet count or other clinical indications of HIT; and patients clinically defined as HIT positive. Using the serotonin release test as the gold standard, the sensitivity and specificity of the Asserachrom HPIA antiheparin/PF 4 antibody ELISA (Diagnostica Stago) were 73% and 77%, respectively. The sensitivity and specificity for the GTI-HAT ELISA (GTI Inc., Brookfield, WI, U.S.A.) were 60% and 93%, respectively. In patients whose plasma was negative by the serotonin release test, the ELISAs detected antiheparin/PF 4 antibodies in 25% and 9% of patients, respectively. Antibodies to heparin/PF 4 were detected by HPIA in 18% of samples that were negative by the GTI-HAT ELISA and the serotonin release test.
Samples from certoparin-treated patients were evalu-ated prior to the administration of the drug and at 4-day intervals up to 16 days during treatment. GTI-HAT identified antiheparin/PF 4 antibodies in 50% of these patients, with antibodies detected after 12 days of certoparin therapy. HPIA identified the antibodies in 75% of these patients, with detection of antibodies 4 days after the initiation of certoparin. A direct comparison of the two ELISA methods in 105 samples showed a reasonable correlation (r 2 = 0.82) (16) .
This study shows that the results of two ELISA tests may differ and that both tests can provide positive and negative results that do not correlate with the serotonin release findings or clinical symptoms of HIT.
Inhibition of HIT-induced platelet activation by heparinase
Heparinase is an enzyme that degrades heparin and LMWHs, thereby inhibiting the anticoagulant/antithrombotic actions of these agents. Heparinase is being developed for clinical use as an antagonist to heparin (IBEX Technologies, Montreal, Canada). An in vitro study was performed in which the effect of heparinase on HIT serum (n = 8)/heparin (0.1 IU/mL)-induced platelet activation was studied using platelet aggregometry and flow cytometry (36) . A concentration-dependent inhibition of the aggregation response was observed with heparinase concentrations in the range of 0.01 to 0.25 IU/mL (p < .01) (Fig. 3 ). With increasing concentrations of heparinase, the time to an aggregation response was prolonged until the response was completely abolished. It FIG. 3 . The effect of heparinase on HIT serum-mediated platelet activation was measured using whole blood flow cytometry. Donor whole blood (multiple donors) was incubated with HIT serum (n = 8) and heparin (0.1 U/mL) in the presence of increasing concentrations of heparinase. Heparinase concentrationdependent inhibited platelet activation as measured by microparticle formation (and P-selectin expression). was previously shown that incubation of HIT-positive serum with heparinized donor whole blood results in a significant increase in platelet P-selectin expression and microparticle formation (indicative of platelet activation) as measured by flow cytometry. Addition of heparinase at concentrations of 0.035 to 0.089 IU/mL concentrationdependent inhibited platelet activation as measured using these parameters.
These results suggest that heparinase may be useful for treatment of the acute phase of HIT to remove the stimulant of the immunologic response (36) .
Clinical experience of alternate anticoagulation without testing for cross-reactivity
The following case report refers to a 40-year-old male patient with multiorgan failure due to pneumococcus sepsis who required hemofiltration. The profile of platelet counts and urine production are shown in Figure 4 . The patient received heparin for 10 days with no complications. However, between day 10 and day 12, the platelet count dropped significantly and the hemofiltration system was obstructed by blood clots. The HPIA heparin/PF 4 antibody titer was highly positive. Heparin was discontinued and Orgaran8 was initiated prior to the results of cross-reactivity testing becoming available.
Upon initiation of Orgaran8 therapy there was a marginal increase of platelets for 2 days, though the production of urine did not recover. After the results of the in vitro testing revealed a cross-reactivity of Orgarang to the heparin antibodies, this agent was discontinued. Due to the patient's underlying renal insufficiency there was a significant accumulation of anti-Xa activity in the blood signaling a contraindication for any other anticoagulant substance because of the high risk of bleeding. Although no alternative anticoagulant was given during the following 9 days, the platelet count and urine production recovered spontaneously. When baseline levels of anti-Xa activity were reachieved, therapy with rhirudin (RefludanO) was initiated with a successful recovery from all symptoms of HIT.
This case report indicates that a switch from heparin to OrgaranO is not recommended without in vitro testing for cross-reactivity. In such a case, an immediate administration of r-hirudin or another thrombin inhibitor would be preferred because of the demonstrated lack of crossreactivity of these drugs to the heparin antibody.
DISCUSSION
In various clinical trials we have recognized that many patients can form HIT-IgG in response to heparin use without developing thrombocytopenia, thrombosis, or other manifestations of HIT type II. Therefore, because of the low positive predictive value for the development of clinically manifest HIT, a routine screening of clinically asymptomatic patients for antiheparin/PF 4 anti- FIG. 4 . Time course of platelet count and urine production in a patient with HIT treated with danaparoid. Following a fall in platelet count while on heparin, the patient was switched to danaparoid prior to obtaining the results of in vitro cross-reactivity testing. When the patient failed to improve on danaparoid, r-hirudin therapy was initiated. The patient's platelet count and urine production improved while on r-hirudin therapy. , bodies is not recommended. It is likely that various patient-dependent variables (e.g., heterogeneity of platelet Fc receptor number or function) modulate the risk for thrombocytopenia and thrombosis among patients who form HIT-IgG. Testing for HIT antibodies in the absence of a decrease in platelet count is appropriate for patients who develop very unusual events, such as skin lesions at heparin injection sites.
Heparin-induced thrombocytopenia type II is a clinicopathologic syndrome, which ideally should be confirmed by laboratory testing. Functional and antigenic assays may be combined, since antigen testing alone may lead to assay-dependent results. In our comparative studies on the 14C-serotonin release test and the immunoassays for the laboratory diagnosis of HIT, we were able to show that the currently available ELISA methods for the detection of antiheparin/PF 4 antibodies offer varying sensitivities and specificities for the detection of these antibodies. Therefore, for the laboratory diagnosis of HIT type II, the currently available ELISA methods are of limited value.
Heparin therapy should be discontinued and an alternative anticoagulant therapy started if there is clinical suspicion of HIT type II. Interest in LMWH as a possible treatment for HIT type II resulted from earlier observations that these preparations cause less direct (nonimmune) platelet aggregation than does heparin. Moreover, LMWH appears to be less likely to trigger formation of HIT-IgG and less likely to cause HIT type II than heparin. Unfortunately, these advantages of LMWH do not necessarily apply to patients who have already formed HIT-IgG (i.e., there is a high risk for in vitro and in vivo cross-reactivity of the HIT-IgG for LMWH). This is in agreement with our observations on the cross-reactivity of LMWHs with antiheparin/PF 4 antibodies as measured using the '4C-serotonin release assay. These data suggest that LMWHs cross-react with HIT antibodies generated against heparin. Thus, any use of LMWHs in established HIT patients should be avoided and alternate anticoagulants considered.
Other alternative drugs that have been evaluated in significant numbers of patients include danaparoid sodium and various thrombin inhibitors. In case of a switch to danaparoid, completing an in vitro test for crossreactivity of danaparoid to the heparin antibodies before the onset of therapy is highly recommended, or the risk for failure of the alternate antithrombotic therapy may increase. If no testing for cross-reactivity can be performed prior to the administration of danaparoid, an immediate administration of a thrombin inhibitor is preferred. Early in vitro investigations suggest that digestion of heparin by heparinase may be an effective means of limiting the acute phase of the HIT response by removing an important part of the immunologic stimulus.
The current state of the understanding and treatment of patients with HIT has come far in recent years. This syndrome has been known for at least 50 years, yet it is in only the last 5 years that significant progress has been made. However, many unresolved issues remain. The studies reviewed and reported here demonstrate some of the most recent findings in the pathophysiology and treatment of HIT
